PASylation: the Biological Alternative to PEGylation
Conference Recording Jun 03, 2013
About the SpeakerUli Binder studied molecular biotechnology and business administration. He did his Ph.D. studies at the Technische Universität München and has extensive experience in protein engineering.
Short plasma half-life is a major draw-back of most biopharmaceuticals, in particular small proteins and peptides, which can only in few cases be alleviated using depot formulations. Instead, PEGylation of biologics is now widely applied, but has disadvantages with regard to high production cost and tissue accumulation. We have developed PASylation, that is the genetic fusion of a biologic with a voluminous hydrophilic polypeptide composed of Pro, Ala, and/or Ser, as an efficient alternative technology to retard kidney filtration and design better drugs with prolonged action.